Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib

@article{Bubnoff2010IdentificationOA,
  title={Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib},
  author={Nikolas von Bubnoff and Carmen Rummelt and Helge Menzel and Marcus Sigl and Christian Peschel and Justus Duyster},
  journal={Leukemia},
  year={2010},
  volume={24},
  pages={1523-1525}
}
J-J Kiladjian, A Massé, B Cassinat, H Mokrani, I Teyssandier, J-P le Couédic, N Cambier, C Almire, E Pronier, N Casadevall, W Vainchenker, C Chomienne and F Delhommeau, for the French Intergroup of Myeloproliferative Neoplasms (FIM) Centre d’Investigations CliniquesFCIC 9504, Assistance Publique -Hôpitaux de Paris, Hôpital Saint-Louis; Université Paris 7, Paris, France; INSERM U1009, Institut Gustave Roussy, Villejuif, France; Unité de Biologie Cellulaire, Assistance PubliqueFHôpitaux de Paris… CONTINUE READING
7 Citations
11 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 11 references

kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro

  • J Cools, N Mentens, P Furet, D Fabbro, JJ Clark, JD Griffin
  • Cancer Res
  • 2009

or not amenable to conventional therapy for the disease

  • W Zhang, M Konopleva, YX Shi, T McQueen, D Harris, X Ling
  • Blood
  • 2005

Similar Papers

Loading similar papers…